Literature DB >> 35618423

Usefulness of Wave-CAIPI for Postcontrast 3D T1-SPACE in the Evaluation of Brain Metastases.

H J Baek1, Y J Heo2, D Kim3, S Y Yun3, J W Baek3, H W Jeong3, H J Choo3, J Y Lee4, S-I Oh5.   

Abstract

BACKGROUND AND
PURPOSE: High-resolution postcontrast 3D T1WI is a widely used sequence for evaluating brain metastasis, despite the long scan time. This study aimed to compare highly accelerated postcontrast 3D T1-weighted sampling perfection with application-optimized contrasts by using different flip angle evolution by using wave-controlled aliasing in parallel imaging (wave-T1-SPACE) with the commonly used standard high-resolution postcontrast 3D T1-SPACE for the evaluation of brain metastases.
MATERIALS AND METHODS: Among the 387 patients who underwent postcontrast wave-T1-SPACE and standard SPACE, 56 patients with suspected brain metastases were retrospectively included. Two neuroradiologists assessed the number of enhancing lesions according to lesion size, contrast-to-noise ratiolesion/parenchyma, contrast-to-noise ratiowhite matter/gray matter, contrast ratiolesion/parenchyma, and overall image quality for the 2 different sequences.
RESULTS: Although there was no significant difference in the evaluation of larger enhancing lesions (>5 mm) between the 2 different sequences (P = .66 for observer 1, P = .26 for observer 2), wave-T1-SPACE showed a significantly lower number of smaller enhancing lesions (<5 mm) than standard SPACE (1.61 [SD, 0.29] versus 2.84 [SD, 0.47] for observer 1; 1.41 [SD, 0.19] versus 2.68 [SD, 0.43] for observer 2). Furthermore, mean contrast-to-noise ratiolesion/parenchyma and overall image quality of wave-T1-SPACE were significantly lower than those in standard SPACE.
CONCLUSIONS: Postcontrast wave-T1-SPACE showed comparable diagnostic performance for larger enhancing lesions (>5 mm) and marked scan time reduction compared with standard SPACE. However, postcontrast wave-T1-SPACE showed underestimation of smaller enhancing lesions (<5 mm) and lower image quality than standard SPACE. Therefore, postcontrast wave-T1-SPACE should be interpreted carefully in the evaluation of brain metastasis.
© 2022 by American Journal of Neuroradiology.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35618423      PMCID: PMC9172958          DOI: 10.3174/ajnr.A7520

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   4.966


  20 in total

Review 1.  Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials.

Authors:  Benjamin M Ellingson; Martin Bendszus; Jerrold Boxerman; Daniel Barboriak; Bradley J Erickson; Marion Smits; Sarah J Nelson; Elizabeth Gerstner; Brian Alexander; Gregory Goldmacher; Wolfgang Wick; Michael Vogelbaum; Michael Weller; Evanthia Galanis; Jayashree Kalpathy-Cramer; Lalitha Shankar; Paula Jacobs; Whitney B Pope; Dewen Yang; Caroline Chung; Michael V Knopp; Soonme Cha; Martin J van den Bent; Susan Chang; W K Al Yung; Timothy F Cloughesy; Patrick Y Wen; Mark R Gilbert
Journal:  Neuro Oncol       Date:  2015-08-05       Impact factor: 12.300

2.  Diagnostic Performance of a 10-Minute Gadolinium-Enhanced Brain MRI Protocol Compared with the Standard Clinical Protocol for Detection of Intracranial Enhancing Lesions.

Authors:  J Fagundes; M G Longo; S Y Huang; B R Rosen; T Witzel; K Heberlein; R G Gonzalez; P Schaefer; O Rapalino
Journal:  AJNR Am J Neuroradiol       Date:  2017-07-13       Impact factor: 3.825

3.  The measurement of observer agreement for categorical data.

Authors:  J R Landis; G G Koch
Journal:  Biometrics       Date:  1977-03       Impact factor: 2.571

4.  Validation of Highly Accelerated Wave-CAIPI SWI Compared with Conventional SWI and T2*-Weighted Gradient Recalled-Echo for Routine Clinical Brain MRI at 3T.

Authors:  J Conklin; M G F Longo; S F Cauley; K Setsompop; R G González; P W Schaefer; J E Kirsch; O Rapalino; S Y Huang
Journal:  AJNR Am J Neuroradiol       Date:  2019-11-14       Impact factor: 3.825

5.  Compressed Sensing-Sensitivity Encoding (CS-SENSE) Accelerated Brain Imaging: Reduced Scan Time without Reduced Image Quality.

Authors:  J E Vranic; N M Cross; Y Wang; D S Hippe; E de Weerdt; M Mossa-Basha
Journal:  AJNR Am J Neuroradiol       Date:  2018-12-06       Impact factor: 3.825

6.  Clinical Feasibility of Ultrafast Contrast-Enhanced T1-Weighted 3D-EPI for Evaluating Intracranial Enhancing Lesions in Oncology Patients: Comparison with Standard 3D MPRAGE Sequence.

Authors:  K H Ryu; H J Baek; S Skare; E Cho; I C Nam; T H Kim; T Sprenger
Journal:  AJNR Am J Neuroradiol       Date:  2022-01-13       Impact factor: 3.825

7.  Usefulness of the Delay Alternating with Nutation for Tailored Excitation Pulse with T1-Weighted Sampling Perfection with Application-Optimized Contrasts Using Different Flip Angle Evolution in the Detection of Cerebral Metastases: Comparison with MPRAGE Imaging.

Authors:  D Kim; Y J Heo; H W Jeong; J W Baek; J-Y Han; J Y Lee; S-C Jin; H J Baek
Journal:  AJNR Am J Neuroradiol       Date:  2019-08-01       Impact factor: 3.825

8.  Usefulness of contrast-enhanced T1-weighted sampling perfection with application-optimized contrasts by using different flip angle evolutions in detection of small brain metastasis at 3T MR imaging: comparison with magnetization-prepared rapid acquisition of gradient echo imaging.

Authors:  Y Kato; S Higano; H Tamura; S Mugikura; A Umetsu; T Murata; S Takahashi
Journal:  AJNR Am J Neuroradiol       Date:  2009-02-12       Impact factor: 3.825

9.  Comparison of contrast-enhanced modified T1-weighted 3D TSE black-blood and 3D MP-RAGE sequences for the detection of cerebral metastases and brain tumours.

Authors:  N N Kammer; E Coppenrath; K M Treitl; H Kooijman; O Dietrich; T Saam
Journal:  Eur Radiol       Date:  2015-09-03       Impact factor: 5.315

10.  Lesion enhancement in radio-frequency spoiled gradient-echo imaging: theory, experimental evaluation, and clinical implications.

Authors:  S Rand; K R Maravilla; U Schmiedl
Journal:  AJNR Am J Neuroradiol       Date:  1994-01       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.